Advertisement
PerkinElmer
PerkinElmer

Bio Business

» FDA and biotech

Most Recent

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

image: That Loving Feeling

That Loving Feeling

By | July 1, 2014

There are no FDA-approved drugs to treat low sexual desire in women, but not for lack of trying.

1 Comment

image: Incubator Boom

Incubator Boom

By | March 1, 2014

From San Francisco to St. Louis, biotech incubators are proliferating across North America. Can they deliver on their promise of fueling the economy?  

1 Comment

image: Penetrating the Brain

Penetrating the Brain

By | November 1, 2013

Researchers use molecular keys, chisels, and crowbars to open the last great biochemical barricade in the body—the blood-brain barrier.

2 Comments

image: Remaking a Classic

Remaking a Classic

By | September 1, 2013

Companies are bursting at the seams with tools to engineer pharma’s next magic bullet: the new and improved antibody.

0 Comments

image: How Safe Is Your Medicine Cabinet?

How Safe Is Your Medicine Cabinet?

By | May 1, 2013

After numerous high-profile safety scares, clinicians and regulators push to fix critical weaknesses in the FDA’s monitoring system for approved drugs.

1 Comment

image: The Little Cell That Could

The Little Cell That Could

By | July 1, 2012

Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.

1 Comment

image: Braving the IPO Drought

Braving the IPO Drought

By | March 1, 2012

Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.

0 Comments

image: New Tech Boosts Science

New Tech Boosts Science

By | October 1, 2011

From iPhone apps to cloud computing, everyday digital technologies are helping advance drug discovery, conduct clinical trials, and improve medical care.

1 Comment

image: Make Mine Rare

Make Mine Rare

By | August 1, 2011

With mounting interest from biotechs, Big Pharma, and the federal government, research on rare diseases is burgeoning.

6 Comments

Advertisement

Popular Now

  1. Opinion: Too Many Mitochondrial Genome Papers
  2. Antibiotics and the Gut Microbiome
  3. Sex Differences in Pain Pathway
  4. The Sum of Our Parts
    Features The Sum of Our Parts

    Putting the microbiome front and center in health care, in preventive strategies, and in health-risk assessments could stem the epidemic of noncommunicable diseases.

Advertisement
The Scientist